SCHEMBL29516335

SCHEMBL29516335

CC(=O)Nc1ccc(-c2csc(NC(=O)CCCCCCSC(=O)CCc3ccccc3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.61
▸ KMT2A Q03164 8/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ MAPT P10636 4/20 0.61
▸ LMNA P02545 3/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ RAB9A P51151 2/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ POLB P06746 1/20 0.61
▸ GAA P10253 1/20 0.58
▸ PKM P14618 1/20 0.58
▸ HDAC1 Q13547 8/20 0.56
▸ HDAC2 Q92769 7/20 0.56
▸ HDAC3 O15379 7/20 0.56
▸ HDAC6 Q9UBN7 7/20 0.56
▸ HDAC10 Q969S8 6/20 0.56
▸ HDAC9 Q9UKV0 6/20 0.56
▸ HDAC4 P56524 5/20 0.56
▸ HDAC7 Q8WUI4 5/20 0.56
▸ HDAC11 Q96DB2 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516107 0.96 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL24359615 0.91 HDAC1 (0.67) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL29516155 0.90 HDAC1 (0.64) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL29516132 0.88 HDAC1 (0.64) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL29515970 0.88 HDAC1 (0.59) MEN1KMT2ALMNAGAAHDAC1
SCHEMBL29515953 0.88 MAPT (0.63) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL29516174 0.86 HDAC1 (0.57) MEN1KMT2AMAPTLMNARAB9A
SCHEMBL29516272 0.86 HDAC1 (0.54) MAPTLMNAHDAC1HDAC2HDAC3
SCHEMBL29516173 0.86 HDAC1 (0.66) MAPTHDAC1HDAC2HDAC3HDAC6
SCHEMBL29516151 0.84 HDAC1 (0.61) MEN1KMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-03 — — US disclosed
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327427-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN2, PSEN1, CHAT MEN1 4296/4885KMT2A 3468/4885ALDH1A1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback